Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 14 at 2:00 PM EDT

Register Free →

ENDO PHARMACEUTICALS, INC.;100 ENDO BLVD;CHADDS FORD;PA;193179690

UEI: SLED_71C83D466A9721B7

ENDO PHARMACEUTICALS, INC.;100 ENDO BLVD;CHADDS FORD;PA;193179690 is a federal contractor, registered under UEI SLED_71C83D466A9721B7. It has been awarded $420,000,000 across 1 federal contract. Primary work spans Pharmaceutical Preparation Manufacturing. Top awarding agencies include Nac Federal Supply Schedule (36F797).

Contact Information

Registration and classification details

Registration

UEI Code

SLED_71C83D466A9721B7

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

Endo Pharmaceuticals, Inc. operates within the pharmaceutical manufacturing sector, specifically focusing on the production of pharmaceutical preparations. The company maintains a procurement relationship with the Nac Federal Supply Schedule. The contractor's primary industry focus is categorized ...

Endo Pharmaceuticals, Inc. operates within the pharmaceutical manufacturing sector, specifically focusing on the production of pharmaceutical preparations. The company maintains a procurement relationship with the Nac Federal Supply Schedule. The contractor's primary industry focus is categorized under NAICS 325412, which pertains to the manufacturing of pharmaceutical preparations.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
Awards by NAICS
Awards by Agency Over Time
Awards by Place of Performance

Compete with ENDO PHARMACEUTICALS, INC.;100 ENDO BLVD;CHADDS FORD;PA;193179690

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for ENDO PHARMACEUTICALS, INC.;100 ENDO BLVD;CHADDS FORD;PA;193179690

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS

Open opportunities in ENDO PHARMACEUTICALS, INC.;100 ENDO BLVD;CHADDS FORD;PA;193179690's top NAICS codes and agencies

NAICS: 325412
New
Federal
6505--Latanoprost Ophthalmic Solution (VA-27-00006027)
Solicitation # 36E79727R0039
The Department of Veterans Affairs Enterprise Procurement Office is initiating an unrestricted procurement under solicitation 36E79727R0039 for Latanoprost Ophthalmic Solution. This acquisition aims to establish an uninterrupted source of supply for the VA, including Consolidated Mail Order Pharmacies and Option 2 State Veterans Homes, as well as the Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Centers. The contract will be awarded to a single responsible offeror for a base period of one year with four pre-priced one-year option periods. Distribution will be managed through the respective Pharmaceutical Prime Vendor Programs of the VA and DoD. The procurement is issued in commercial item format per FAR Part 12 under NAICS code 325412 and is subject to the World Trade Organization Government Procurement Agreement and Free Trade Agreements. Strict labeling requirements are in place, requiring offerors to provide a unique NDC number and the exact drug name as it appears on the label. The contractor's label must be the sole label on the product, cannot be affixed over another label, and must allow VA labels to adhere securely on top. Additionally, vendors must comply with the American Academy of Ophthalmology’s uniform color-coding system for caps and labels. The solicitation is expected to be issued around October 21, 2026, with a tentative closing date of November 4, 2026, though some metadata indicates a response deadline of October 16, 2026.
Nac Pharmaceuticals (36E797)

POSTED

about 22 hours ago

DEADLINE

in 13 days
View Details